An Ultrapotent Neutralizing Bispecific Antibody with Broad Spectrum Against SARS-CoV-2 Variants

Hui Zhang,Haohui Huang,Rong Li,Lu Zhang,Zhiwei Wang,Shide Liang,Jiaping Li,Junyou Chen,Huafei Su,Dandan Zheng,Ziqi Su,Li Wang,Chunping Deng,Shujun Pei,Shenghua Zhu,Chan Li,Yaochang Yuan,Haitao Yue,Yanqun Wang,Xiaobo Li,Cuihua Liu,Jinchen Yu,Shengfeng Li,Xianming Huang

DOI: https://doi.org/10.21203/rs.3.rs-951257/v1

2021-01-01

Abstract:Abstract Some variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are threatening our global efforts of herd immunity, novel and more efficacious agents are urgently needed. We have developed a bispecific antibody, 2022, which bonds with high affinity to two non-overlapping epitopes on the receptor-binding domain (RBD) simultaneously, blocks the binding of RBD to human angiotensin-converting enzyme 2 (ACE2), and potently neutralizes SARS-CoV-2 and all of the variants tested, including variants carrying mutations known to resist neutralizing antibodies approved under Emergency Use Authorization (EUA) and reduce the efficacy of existing vaccines. In a mouse model of SARS-CoV-2, 2022 showed strong prophylactic and therapeutic effects. A single administration of 2022 completely protected all mice from bodyweight loss, as compared with up to 20% loss of bodyweight in placebo treated mice, reduced the lung viral titers to undetectable in all mice treated with 2022 either prophylactically or therapeutically, as compared with around 1X105 pfu/g lung tissue in placebo treated mice. In summary, bispecific antibody 2022 showed potent binding and neutralizing activity across a variety of SARS-CoV-2 variants and could be an attractive weapon to combat the ongoing waves of the COVID-19 pandemic.